SynthesisAging and disease2025
Advancing Single-Cell Transcriptomic Analysis to Reveal Age-Related Skeletal Muscle Changes: A Systematic Review.
Synthesis in Aging and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The ageing microenvironment in sarcopenia: early alterations and targeted therapeutic strategies.Frontiers in immunology · 2026Review
- S100A9 as a shared biomarker and mediator of metabolic dysfunction in peripheral artery disease and sarcopenia.Frontiers in genetics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Population aging has become a widespread health problem that leads to huge socioeconomic burden. Skeletal muscle as an important component of motor system, gradually degenerates with age. Age-related muscle disorders, such as sarcopenia is associated with higher risks of falls, fracture, disability, and mortality in old people. As there is still no Food and Drug Administration (FDA) approved drug to treat sarcopenia, conducting research of in-depth mechanisms is warranted to develop novel treatments. The cutting-edge techniques single-cell and single-nuclei RNA sequencing can help to address this issue by discovering age-related changes of muscle at the single-cell level. This review aims to systematically explore current evidence of age-related muscle changes during normal aging, regeneration, and after treatments at the single-cell level. 29 studies were eligible and included in the current review according to the PRISMA guideline. The muscle cell composition was altered with age, such as diminished muscle stem cells (MuSCs), vascular cells, Schwann cells, and increased myocytes as well as some types of immune cells. Inflammation levels, collagen and extracellular matrix (ECM) signaling, protein catabolism, TGFβ signaling, apoptosis, and autophagy of MuSCs, myocytes, fibro-adipogenic progenitor cells, vascular cells, or immune cells were regulated with age. Delayed muscle regeneration of aged muscle was relied on disorders of cell-specific immune response, myogenesis, angiogenesis, and ECM remodeling. Three treatments involved in this review could reverse age-related dysfunction of muscle cells to some extent. Further research targeting age-related changes of muscle at the single-cell level is an important tool in assisting development of more effective treatments for sarcopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.